Publications by authors named "M A Olivella"

Sirtuin 7 (SIRT7) is a member of the mammalian family of nicotinamide adenine dinucleotide (NAD)-dependent histone/protein deacetylases, known as sirtuins. It acts as a potent oncogene in numerous malignancies, but the molecular mechanisms employed by SIRT7 to sustain lung cancer progression remain largely uncharacterized. We demonstrate that SIRT7 exerts oncogenic functions in lung cancer cells by destabilizing the tumor suppressor alternative reading frame (ARF).

View Article and Find Full Text PDF

The objective of the study is to evaluate the evolving phenotype and genetic spectrum of patients with succinic semialdehyde dehydrogenase deficiency (SSADHD) in long-term follow-up. Longitudinal clinical and biochemical data of 22 pediatric and 9 adult individuals with SSADHD from the patient registry of the International Working Group on Neurotransmitter related Disorders (iNTD) were studied with in silico analyses, pathogenicity scores and molecular modeling of ALDH5A1 variants. Leading initial symptoms, with onset in infancy, were developmental delay and hypotonia.

View Article and Find Full Text PDF
Article Synopsis
  • GRIN-related disorders are rare developmental conditions in children caused by genetic variants, which often lead to various cognitive and behavioral challenges with few treatment options available.
  • A non-randomized phase 2A trial tested L-serine as a potential treatment for these disorders in children aged 2-18, measuring its safety and efficacy over a 52-week period using several behavioral and cognitive assessment tools.
  • Twenty-four participants were included in the study, showing improvements in specific skill areas, particularly in children with milder impairments, demonstrating promise for L-serine as a therapeutic option for those with GRIN genetic variants.
View Article and Find Full Text PDF

The study of inborn errors of neurotransmission has been mostly focused on monoamine disorders, GABAergic and glycinergic defects. The study of the glutamatergic synapse using the same approach than classic neurotransmitter disorders is challenging due to the lack of biomarkers in the CSF. A metabolomic approach can provide both insight into their molecular basis and outline novel therapeutic alternatives.

View Article and Find Full Text PDF